HC Wainwright Issues Negative Outlook for OLMA Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for Olema Pharmaceuticals in a research report issued on Monday, June 2nd. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.70) per share for the quarter, down from their previous estimate of ($0.37). HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for Olema Pharmaceuticals' current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals' Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.92) EPS and FY2026 earnings at ($3.86) EPS.

A number of other research analysts also recently issued reports on OLMA. JPMorgan Chase & Co. reduced their price objective on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Friday, March 28th. The Goldman Sachs Group cut their price objective on shares of Olema Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, Oppenheimer cut their price target on shares of Olema Pharmaceuticals from $25.00 to $22.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th.

Olema Pharmaceuticals Price Performance

NASDAQ:OLMA traded down $0.01 during mid-day trading on Wednesday, reaching $4.21. 846,793 shares of the company's stock traded hands, compared to its average volume of 826,227. The company has a 50 day moving average price of $4.46 and a 200-day moving average price of $5.51. The firm has a market capitalization of $288.05 million, a price-to-earnings ratio of -1.92 and a beta of 1.99. Olema Pharmaceuticals has a 12-month low of $2.86 and a 12-month high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its holdings in Olema Pharmaceuticals by 110.6% during the fourth quarter. Bank of America Corp DE now owns 865,339 shares of the company's stock valued at $5,045,000 after purchasing an additional 454,400 shares during the period. Renaissance Technologies LLC lifted its position in Olema Pharmaceuticals by 435.0% in the fourth quarter. Renaissance Technologies LLC now owns 157,300 shares of the company's stock worth $917,000 after buying an additional 127,900 shares during the last quarter. HighTower Advisors LLC bought a new position in Olema Pharmaceuticals during the 4th quarter valued at about $510,000. Millennium Management LLC boosted its position in shares of Olema Pharmaceuticals by 1,154.4% during the fourth quarter. Millennium Management LLC now owns 979,219 shares of the company's stock valued at $5,709,000 after buying an additional 901,159 shares during the period. Finally, Paradigm Biocapital Advisors LP grew its stake in shares of Olema Pharmaceuticals by 32.7% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,304,970 shares of the company's stock valued at $42,588,000 after buying an additional 1,801,370 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.